BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+5.04%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.97B
AUM Growth
-$106M
(-1.5%)
Cap. Flow
-$278M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$25.6M |
| 2 |
Celldex Therapeutics
CLDX
|
$24.6M |
| 3 |
Exact Sciences
EXAS
|
$12.1M |
| 4 |
Tandem Diabetes Care
TNDM
|
$12M |
| 5 |
Charles River Laboratories
CRL
|
$6.28M |
Top Sells
| 1 |
RDUS
Radius Health, Inc.
RDUS
|
$91.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
$42.4M |
| 3 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$26.3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$20.3M |
| 5 |
Axsome Therapeutics
AXSM
|
$14.3M |
Sector Composition
| 1 | Healthcare | 99.34% |
| 2 | Industrials | 0.59% |
| 3 | Energy | 0.02% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Fate Therapeutics
FATE
$115M
| $84M | 1.2% |
3,746,086
+196,000
| +6% | +$4.39M |
|
|
27
Sarepta Therapeutics
SRPT
$1.98B
| $83.6M | 1.2% |
755,898
-383,557
| -34% | -$42.4M |
|
28
Option Care Health
OPCH
$4.7B
| $82.7M | 1.19% |
2,629,172
-258,087
| -9% | -$8.12M |
|
29
Molina Healthcare
MOH
$9.6B
| $79.4M | 1.14% |
240,590
-7,723
| -3% | -$2.55M |
|
|
SWAV
30
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $76.8M | 1.1% |
276,132
-94,567
| -26% | -$26.3M |
|
|
31
Tandem Diabetes Care
TNDM
$834M
| $74.9M | 1.08% |
1,566,015
+250,142
| +19% | +$12M |
|
32
Becton Dickinson
BDX
$54.3B
| $74.6M | 1.07% |
334,838
-8,144
| -2% | -$1.81M |
|
33
Inspire Medical Systems
INSP
$2.53B
| $71.3M | 1.02% |
401,768
-5,289
| -1% | -$938K |
|
34
DexCom
DXCM
$30.9B
| $69.3M | 0.99% |
860,460
-68,048
| -7% | -$5.48M |
|
35
Insmed
INSM
$30.3B
| $69.2M | 0.99% |
3,214,704
-406,858
| -11% | -$8.76M |
|
36
Apellis Pharmaceuticals
APLS
$3.51B
| $68.8M | 0.99% |
1,007,444
-198,978
| -16% | -$13.6M |
|
37
Evolent Health
EVH
$1.11B
| $67.2M | 0.96% |
1,869,055
-149,466
| -7% | -$5.37M |
|
38
Humana
HUM
$37.5B
| $65.1M | 0.93% |
134,206
-11,103
| -8% | -$5.39M |
|
39
CRISPR Therapeutics
CRSP
$4.82B
| $60.7M | 0.87% |
928,305
+6,300
| +0.7% | +$412K |
|
|
AMED
40
DELISTED
Amedisys
AMED
| $58M | 0.83% |
598,934
+13,780
| +2% | +$1.33M |
|
41
HCA Healthcare
HCA
$95.4B
| $52.5M | 0.75% |
285,789
-6,982
| -2% | -$1.28M |
|
42
Cigna
CI
$80.2B
| $52.4M | 0.75% |
188,701
-4,956
| -3% | -$1.38M |
|
|
43
Charles River Laboratories
CRL
$7.99B
| $51.8M | 0.74% |
262,993
+31,924
| +14% | +$6.28M |
|
|
44
Celldex Therapeutics
CLDX
$1.57B
| $50.6M | 0.73% |
1,800,000
+875,000
| +95% | +$24.6M |
|
45
Medtronic
MDT
$118B
| $49.7M | 0.71% |
615,926
-29,580
| -5% | -$2.39M |
|
|
SILK
46
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $47.1M | 0.68% |
1,047,356
+70
| +0% | +$3.15K |
|
47
CareDx
CDNA
$678M
| $44.3M | 0.64% |
2,601,446
+63,922
| +3% | +$1.09M |
|
48
Bio-Rad Laboratories Class A
BIO
$7.8B
| $42.5M | 0.61% |
101,818
+10,657
| +12% | +$4.45M |
|
49
Exelixis
EXEL
$9.95B
| $41.9M | 0.6% |
2,673,500
-5,000
| -0.2% | -$78.4K |
|
50
Centene
CNC
$14.8B
| $41.1M | 0.59% |
528,440
-17,463
| -3% | -$1.36M |
|